DocGo Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Tue, August 18, 2026 at 3:30 PM GMT+3 3 min read

DCGO -11.51%

DocGo Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Transformation and Operational Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management characterized Q2 as a transformational period defined by the definitive agreement to acquire Hicuity Health, marking the company's largest acquisition to date.
The acquisition is designed to bridge the gap between hospital and home care, creating a vertically integrated platform that matches clinicians with patients across the entire care continuum.
Performance attribution for the quarter was heavily influenced by the wind-down of migrant-related projects, which masked a 19% year-over-year revenue increase in core business lines.
Operational improvements were driven by a substantial corporate reduction in force, yielding approximately $4.5 million in annual SG&A savings.
Management highlighted the deployment of over 10 active AI efficiency programs, notably in mobile phlebotomy where AI now handles 60% of inbound and 100% of outbound scheduling calls.
Strategic positioning focused on high-margin verticals, with non-migrant mobile health revenues surging 78% due to growth in care gap closures and remote patient monitoring.
The Hicuity acquisition includes a new funding commitment from Perceptive Advisors, which management believes will reshape the balance sheet and provide flexibility for future growth.

Outlook and Guidance Assumptions

Management expects to achieve a positive adjusted EBITDA run rate by the end of 2026, despite widening the full-year EBITDA loss guidance due to slower-than-expected cost-cutting realization.
Revenue guidance for 2026 was narrowed to $305 million-$310 million, representing 21%-23% growth over 2025 base revenues, excluding any potential Hicuity contributions.
The company anticipates significant cost synergies from the Hicuity deal, including combining shared corporate functions and streamlining clinical operations across 30 states.
Growth in the second half of 2026 is expected to be driven by a large enterprise deal with a leading online pharmacy and seasonal volume increases in the SteadyMD virtual care business.
Management plans to launch an additional 20 efficiency-related programs in late 2026 and early 2027 to further optimize eligibility determination and patient care reporting.

Risk Factors and Structural Changes

Medical transportation gross margins were restrained by higher-than-planned effective hourly wages and a significant rise in fuel costs to $4.27 per gallon.
The company reported a $6.3 million adjusted EBITDA loss for Q2, though this represented a 40% sequential improvement from the prior quarter.
Management addressed potential CMS regulatory changes to Remote Patient Monitoring (RPM), noting that only 2,000 of their 55,000 monitored patients are in the at-risk category.
Cash and equivalents declined to $48.1 million at quarter-end, though the new Perceptive Advisors debt facility is expected to replace the existing asset-backed line of credit.

Q&A Session Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Hicuity Health customer overlap and cross-sell opportunities

Management identified significant overlap with existing hospital system partners, providing opportunities to cross-sell in-person home services like mobile phlebotomy to virtual care patients.
The acquisition strengthens the link between hospital discharge and home care, where DocGo has previously demonstrated a 50%-60% reduction in hospital readmissions.

Impact of proposed CMS reimbursement changes for RPM

Management clarified that the vast majority of their 55,000 monitored patients are cardiac patients with implantable devices, which are not subject to the proposed CMS rate cuts.
The company is shifting focus toward Chronic Care Management (CCM) and Transitional Care Management (TCM), which reward managing conditions rather than just data collection.

Path to EBITDA breakeven by year-end 2026

The path to breakeven relies on a combination of seasonal revenue growth in SteadyMD, improved gross margins as field labor overtime declines, and the full impact of recent SG&A reductions.
Management expects gross margins to normalize as aggressive hiring for SteadyMD concludes and higher-margin service lines like mobile phlebotomy scale.